Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2024-2031

Report ID: 934878 | Published Date: Apr 2024 | No. of Page: 126 | Base Year: 2023 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Biologics
        1.2.3 Biosimilars
    1.3 Market by Application
        1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Immunology
        1.3.3 Endocrinology
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2016-2027)
    2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
        2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2016-2021)
        2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027)
    2.3 Non-oncology Biopharmaceuticals Industry Dynamic
        2.3.1 Non-oncology Biopharmaceuticals Market Trends
        2.3.2 Non-oncology Biopharmaceuticals Market Drivers
        2.3.3 Non-oncology Biopharmaceuticals Market Challenges
        2.3.4 Non-oncology Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
        3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2016-2021)
        3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2016-2021)
    3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
    3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
        3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2020
    3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
    3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
    3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Non-oncology Biopharmaceuticals Breakdown Data by Type
    4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021)
    4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027)

5 Non-oncology Biopharmaceuticals Breakdown Data by Application
    5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021)
    5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027)
    6.2 North America Non-oncology Biopharmaceuticals Market Size by Type
        6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
        6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
        6.2.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
    6.3 North America Non-oncology Biopharmaceuticals Market Size by Application
        6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
        6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
        6.3.3 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
    6.4 North America Non-oncology Biopharmaceuticals Market Size by Country
        6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
        6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027)
    7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type
        7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
        7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
        7.2.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
    7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application
        7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
        7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
        7.3.3 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
    7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country
        7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
        7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027)
    8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type
        8.2.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
    8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application
        8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
    8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
        8.4.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027)
    9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type
        9.2.1 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
        9.2.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
        9.2.3 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
    9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application
        9.3.1 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
        9.3.2 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
        9.3.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
    9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country
        9.4.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
        9.4.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027)
    10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type
        10.2.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
    10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application
        10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
    10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
        10.4.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
        11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 Sanofi
        11.2.1 Sanofi Company Details
        11.2.2 Sanofi Business Overview
        11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
        11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.2.5 Sanofi Recent Development
    11.3 Johnson & Johnson
        11.3.1 Johnson & Johnson Company Details
        11.3.2 Johnson & Johnson Business Overview
        11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
        11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.3.5 Johnson & Johnson Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Details
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
        11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.4.5 Pfizer Recent Development
    11.5 Novo Nordisk
        11.5.1 Novo Nordisk Company Details
        11.5.2 Novo Nordisk Business Overview
        11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
        11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.5.5 Novo Nordisk Recent Development
    11.6 Novartis
        11.6.1 Novartis Company Details
        11.6.2 Novartis Business Overview
        11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
        11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.6.5 Novartis Recent Development
    11.7 Merck
        11.7.1 Merck Company Details
        11.7.2 Merck Business Overview
        11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
        11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.7.5 Merck Recent Development
    11.8 Teva
        11.8.1 Teva Company Details
        11.8.2 Teva Business Overview
        11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
        11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.8.5 Teva Recent Development
    11.9 Eli Lilly
        11.9.1 Eli Lilly Company Details
        11.9.2 Eli Lilly Business Overview
        11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
        11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.9.5 Eli Lilly Recent Development
    11.10 Bristol-Myers Squibb
        11.10.1 Bristol-Myers Squibb Company Details
        11.10.2 Bristol-Myers Squibb Business Overview
        11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
        11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.10.5 Bristol-Myers Squibb Recent Development
    11.11 GlaxoSmithKline
        11.11.1 GlaxoSmithKline Company Details
        11.11.2 GlaxoSmithKline Business Overview
        11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
        11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.11.5 GlaxoSmithKline Recent Development
    11.12 UCB Pharma
        11.12.1 UCB Pharma Company Details
        11.12.2 UCB Pharma Business Overview
        11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
        11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.12.5 UCB Pharma Recent Development
    11.13 Amgen
        11.13.1 Amgen Company Details
        11.13.2 Amgen Business Overview
        11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
        11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.13.5 Amgen Recent Development
    11.14 AbbVie
        11.14.1 AbbVie Company Details
        11.14.2 AbbVie Business Overview
        11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
        11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.14.5 AbbVie Recent Development
    11.15 Takeda
        11.15.1 Takeda Company Details
        11.15.2 Takeda Business Overview
        11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
        11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.15.5 Takeda Recent Development
    11.16 AstraZeneca
        11.16.1 AstraZeneca Company Details
        11.16.2 AstraZeneca Business Overview
        11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
        11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.16.5 AstraZeneca Recent Development
    11.17 Mylan
        11.17.1 Mylan Company Details
        11.17.2 Mylan Business Overview
        11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
        11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.17.5 Mylan Recent Development
    11.18 LEO Pharma
        11.18.1 LEO Pharma Company Details
        11.18.2 LEO Pharma Business Overview
        11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
        11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.18.5 LEO Pharma Recent Development
    11.18 Boehringer Ingelheim
        .1 Boehringer Ingelheim Company Details
        .2 Boehringer Ingelheim Business Overview
        .3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
        .4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        .5 Boehringer Ingelheim Recent Development
    11.20 Alexion Pharmaceuticals
        11.20.1 Alexion Pharmaceuticals Company Details
        11.20.2 Alexion Pharmaceuticals Business Overview
        11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
        11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.20.5 Alexion Pharmaceuticals Recent Development
    11.21 Elusys Therapeutics
        11.21.1 Elusys Therapeutics Company Details
        11.21.2 Elusys Therapeutics Business Overview
        11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
        11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.21.5 Elusys Therapeutics Recent Development
    11.22 Swedish Orphan Biovitrum
        11.22.1 Swedish Orphan Biovitrum Company Details
        11.22.2 Swedish Orphan Biovitrum Business Overview
        11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
        11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.22.5 Swedish Orphan Biovitrum Recent Development
    11.23 Biogen
        11.23.1 Biogen Company Details
        11.23.2 Biogen Business Overview
        11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
        11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
        11.23.5 Biogen Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Biologics
    Table 3. Key Players of Biosimilars
    Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Non-oncology Biopharmaceuticals Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Non-oncology Biopharmaceuticals Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Non-oncology Biopharmaceuticals Market Share by Regions (2016-2021)
    Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
    Table 10. Non-oncology Biopharmaceuticals Market Trends
    Table 11. Non-oncology Biopharmaceuticals Market Drivers
    Table 12. Non-oncology Biopharmaceuticals Market Challenges
    Table 13. Non-oncology Biopharmaceuticals Market Restraints
    Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2016-2021)
    Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020)
    Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
    Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
    Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021)
    Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Roche Company Details
    Table 62. Roche Business Overview
    Table 63. Roche Non-oncology Biopharmaceuticals Product
    Table 64. Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 65. Roche Recent Development
    Table 66. Sanofi Company Details
    Table 67. Sanofi Business Overview
    Table 68. Sanofi Non-oncology Biopharmaceuticals Product
    Table 69. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 70. Sanofi Recent Development
    Table 71. Johnson & Johnson Company Details
    Table 72. Johnson & Johnson Business Overview
    Table 73. Johnson & Johnson Non-oncology Biopharmaceuticals Product
    Table 74. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 75. Johnson & Johnson Recent Development
    Table 76. Pfizer Company Details
    Table 77. Pfizer Business Overview
    Table 78. Pfizer Non-oncology Biopharmaceuticals Product
    Table 79. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 80. Pfizer Recent Development
    Table 81. Novo Nordisk Company Details
    Table 82. Novo Nordisk Business Overview
    Table 83. Novo Nordisk Non-oncology Biopharmaceuticals Product
    Table 84. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 85. Novo Nordisk Recent Development
    Table 86. Novartis Company Details
    Table 87. Novartis Business Overview
    Table 88. Novartis Non-oncology Biopharmaceuticals Product
    Table 89. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 90. Novartis Recent Development
    Table 91. Merck Company Details
    Table 92. Merck Business Overview
    Table 93. Merck Non-oncology Biopharmaceuticals Product
    Table 94. Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 95. Merck Recent Development
    Table 96. Teva Company Details
    Table 97. Teva Business Overview
    Table 98. Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 99. Teva Recent Development
    Table 100. Eli Lilly Company Details
    Table 101. Eli Lilly Business Overview
    Table 102. Eli Lilly Non-oncology Biopharmaceuticals Product
    Table 103. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 104. Eli Lilly Recent Development
    Table 105. Bristol-Myers Squibb Company Details
    Table 106. Bristol-Myers Squibb Business Overview
    Table 107. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
    Table 108. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 109. Bristol-Myers Squibb Recent Development
    Table 110. GlaxoSmithKline Company Details
    Table 111. GlaxoSmithKline Business Overview
    Table 112. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
    Table 113. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 114. GlaxoSmithKline Recent Development
    Table 115. UCB Pharma Company Details
    Table 116. UCB Pharma Business Overview
    Table 117. UCB Pharma Non-oncology Biopharmaceuticals Product
    Table 118. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 119. UCB Pharma Recent Development
    Table 120. Amgen Company Details
    Table 121. Amgen Business Overview
    Table 122. Amgen Non-oncology Biopharmaceuticals Product
    Table 123. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 124. Amgen Recent Development
    Table 125. AbbVie Company Details
    Table 126. AbbVie Business Overview
    Table 127. AbbVie Non-oncology Biopharmaceuticals Product
    Table 128. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 129. AbbVie Recent Development
    Table 130. Takeda Company Details
    Table 131. Takeda Business Overview
    Table 132. Takeda Non-oncology Biopharmaceuticals Product
    Table 133. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 134. Takeda Recent Development
    Table 135. AstraZeneca Company Details
    Table 136. AstraZeneca Business Overview
    Table 137. AstraZeneca Non-oncology Biopharmaceuticals Product
    Table 138. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 139. AstraZeneca Recent Development
    Table 140. Mylan Company Details
    Table 141. Mylan Business Overview
    Table 142. Mylan Non-oncology Biopharmaceuticals Product
    Table 143. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 144. Mylan Recent Development
    Table 145. LEO Pharma Company Details
    Table 146. LEO Pharma Business Overview
    Table 147. LEO Pharma Non-oncology Biopharmaceuticals Product
    Table 148. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 149. LEO Pharma Recent Development
    Table 150. Boehringer Ingelheim Company Details
    Table 151. Boehringer Ingelheim Business Overview
    Table 152. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
    Table 153. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 154. Boehringer Ingelheim Recent Development
    Table 155. Alexion Pharmaceuticals Company Details
    Table 156. Alexion Pharmaceuticals Business Overview
    Table 157. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
    Table 158. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 159. Alexion Pharmaceuticals Recent Development
    Table 160. Elusys Therapeutics Company Details
    Table 161. Elusys Therapeutics Business Overview
    Table 162. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
    Table 163. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 164. Elusys Therapeutics Recent Development
    Table 165. Swedish Orphan Biovitrum Company Details
    Table 166. Swedish Orphan Biovitrum Business Overview
    Table 167. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
    Table 168. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 169. Swedish Orphan Biovitrum Recent Development
    Table 170. Biogen Company Details
    Table 171. Biogen Business Overview
    Table 172. Biogen Non-oncology Biopharmaceuticals Product
    Table 173. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
    Table 174. Biogen Recent Development
    Table 175. Research Programs/Design for This Report
    Table 176. Key Data Information from Secondary Sources
    Table 177. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2020 VS 2027
    Figure 2. Biologics Features
    Figure 3. Biosimilars Features
    Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2027
    Figure 5. Immunology Case Studies
    Figure 6. Endocrinology Case Studies
    Figure 7. Others Case Studies
    Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
    Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Regions: 2020 VS 2027
    Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
    Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Players in 2020
    Figure 14. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2020
    Figure 16. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
    Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027)
    Figure 18. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
    Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
    Figure 21. North America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
    Figure 22. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
    Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
    Figure 27. Europe Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
    Figure 28. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2016-2027)
    Figure 38. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
    Figure 46. Latin America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
    Figure 47. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
    Figure 48. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
    Figure 54. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 58. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 59. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 60. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 61. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 62. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 63. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 64. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 65. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 67. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 68. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 69. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 70. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 71. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 72. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 73. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 74. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 75. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 76. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 77. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 78. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 79. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021)
    Figure 80. Bottom-up and Top-down Approaches for This Report
    Figure 81. Data Triangulation
    Figure 82. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Frequently Asked Questions
Non-oncology Biopharmaceuticals report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-oncology Biopharmaceuticals report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-oncology Biopharmaceuticals report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports